Candidate genetic markers and the risk of restenosis after coronary angioplasty

Clinical Science

Volumn 106, Issue 1, 2004, Pages 35-42

  Völzke, Henry ^a   Grimm, Rita ^a   Robinson, Daniel M ^a   Wolff, Birger ^a   Schwahn, Christian ^a   Hertwig, Sabine ^a   Motz, Wolfgang ^b   Rettig, Rainer ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Heart Center Karlsburg   (Germany)

Author keywords

Coronary angioplasty; Coronary intervention; Gene polymorphism; Percutaneous transluminal coronary angioplasty (PTCA); Restenosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; BLOOD CLOTTING FACTOR 5 LEIDEN; CYSTEINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; GLYCINE; GLYCOPROTEIN IIIA; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; THREONINE; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SUBSTITUTION; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENETIC MARKER; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RESTENOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0346171343     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20030042     Document Type: Article

References (62)

1. Rapold, H. J., David, P. R. G. V. P., Mata, A. L., Crean, P. A. and Bourassa, M. G. (1987) Restenosis and its determinants in first and repeat coronary angioplasty. Eur. Heart J. 8, 575-586
2. Fornitz, G. G., Nielsen, P., Amtorp, O. et al. (2001) Impaired fibrinolysis determines the outcome of percutaneus transluminal coronary angioplasty (PTCA). Eur. J. Clin. Invest. 31, 586-592
3. Osanai, H., Kanayama, H., Miyazaki, Y., Fukushima, A., Shinoda, M. and Ito, T. (1998) Usefulness of enhanced insulin secretion during an oral glucose tolerance test as a predictor of restenosis after direct percutaneous transluminal coronary angioplasty during acute myocardial infarction in patients without diabetes mellitus. Am. J. Cardiol. 81, 698-701
4. Jorgensen, B., Simonsen, S., Endresen, K., Forfang, K., Egeland, T. and Thaulow, E. (2000) Physiologic response to gain and loss in coronary minimal luminal diameter in patients treated with coronary angioplasty: prediction of restenosis on the basis of exercise capacity. Am. Heart J. 139, 482-490
5. Völzke, H., Hertwig, S., Rettig, R. and Motz, W. (2000) The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty. Clin. Sci. 99, 19-25
6. Hertwig, S., Völzke, H., Robinson, D. M., Motz, W. and Rettig, R. (2002) Angiotensinogen M235T gene polymorphism and recurrent restenosis after repeated percutaneous transluminal coronary angioplasty. Clin. Sci. 103, 101-106
7. Montalescot, G., Ankri, A., Vicaut, E., Drobinski, G., Grosgogeat, Y. and Thomas, D. (1995) Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 92, 31-38
8. Sakata, K., Miura, F., Sugino, H. et al. (1996) Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am. Heart J. 131, 1-6
9. Wilhelmsen, L., Svärdsudd, K., Korsan-Bengtsen, K., Larsson, B., Welin, L. and Tibblin, G. (1984) Fibrinogen as a risk factor for stroke and myocardial infarction. N. Engl. J. Med. 311, 501-505
10. Newman, P. J., Derbes, R. S. and Aster, R. H. (1989) The human platelet alloantigens, PIA1 and PIA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J. Clin. Invest. 83, 1778-1781
11. Dawson, S. J., Wiman, B., Hamsten, A., Green, F., Humphries, S. and Henney, A. M. (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J. Biol. Chem. 268, 10739-10745
12. Bertina, R. M., Koeleman, B. P., Koster, T. et al. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (London) 369, 64-67
13. Carter, A. M., Mansfield, M. W., Stickland, M. H. and Grant, P. J. (1996) β-Fibrinogen gene - 455 G/A polymorphism and fibrinogen levels. Diabetes Care 19, 1265-1268
14. Weiss, E. J., Bray, P. F., Tayback, M. et al. (1996) A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N. Engl. J. Med. 334, 1090-1094
15. Mikkelsson, J., Perola, M., Wartiovaara, U. et al. (2000) Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. Thromb. Haemostasis 84, 78-82
16. Vargas, M., Soto, I., Pinto, C. R. et al. (1999) The prothrombin 20210A allele and the factor V Leiden are associated with venous thrombosis but not with early coronary artery disease. Blood Coagulation Fibrinolysis 10, 39-41
17. Varela, M. L., Adamczuk, Y. P., Martinuzzo, M. E. et al. (1999) Early occlusion of coronary by-pass associated with the presence of factor V Leiden and the prothrombin 20210A allele: case report. Blood Coagulation Fibrinolysis 10, 443-446
18. Ross, R. (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (London) 362, 801-809
19. di Giovine, F. S. and Duff, G. W. (1990) Interleukin 1: the first interleukin. Immunol. Today 11, 13-20
20. Tashiro, H., Shimokawa, H., Sadamatsu, K., Aoki, T. and Yamamoto, K. (2001) Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coronary Artery Dis. 12, 107-113
21. Clausell, N., de Lima, V. C., Molossi, S. et al. (1995) Expression of tumour necrosis factor α and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. Br. Heart J. 73, 534-539
22. McDowell, T. L., Symons, J. A., Ploski, R., Forre, O. and Duff, G. W. (1995) A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1α polymorphism. Arthritis Rheum. 38, 221-228
23. di Giovine, F. S., Takhsh, E., Blakemore, A. I. and Duff, G. W. (1992) Single base polymorphism at - 511 in the human interleukin-1 β gene (IL1 β). Hum. Mol. Genet. 1, 450
24. Wilson, A. G., de Vries, N., Pociot, F., di Giovine, F. S., van der Putte, L. B. and Duff, G. W. (1993) An allelic polymorphism within the human tumor necrosis factor α promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J. Exp. Med. 177, 557-560
25. Allen, R. A., Lee, E. M., Roberts, D. H., Park, B. K. and Pirmohamed, M. (2001) Polymorphisms in the TNF-α and TNF-receptor genes in patients with coronary artery disease. Eur. J. Clin. Invest. 31, 843-851
26. Ray, K. K., Camp, N. J., Bennett, C. E., Francis, S. E. and Crossman, D. C. (2002) Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes. Clin. Sci. 103, 303-310
27. Francis, S. E., Camp, N. J., Dewberry, R. M. et al. (1999) Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 99, 861-866
28. Keso, T., Perola, M., Laippala, P. et al. (2001) Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis 154, 691-697
29. Wang, X. L. and Oosterhof, J. (2000) Tumour necrosis factor α G - 308 → A polymorphism and risk for coronary artery disease. Clin. Sci. 98, 435-437
30. Koch, W., Kastrati, A., Bottiger, C., Mehilli, J., von Beckerath, N. and Schomig, A. (2001) Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 159, 137-144
31. Morita, H., Kurihara, H., Kuwaki, T. et al. (2000) Homocysteine as a risk factor for restenosis after coronary angioplasty. Thromb. Haemostasis 84, 27-31
32. Brattstrom, L., Wilcken, D. E., Ohrvik, J. and Brudin, L. (1998) Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98, 2520-2526
33. Wu, A. H. and Tsongalis, G. J. (2001) Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am. J. Cardiol. 87, 1361-1366
34. Wang, Y. and Marsden, P. A. (1995) Nitric oxide synthases: biochemical and molecular regulation. Curr. Opin. Nephrol. Hypertens. 4, 12-22
35. Vallance, P., Collier, J. and Moncada, S. (1989) Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet ii, 997-1000
36. Garg, U. C. and Hassid, A. (1989) Nitric oxide-generating vasodilators and 8-broma-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83, 1774-1777
37. Radomski, M. W., Palmer, R. M. and Moncada, S. (1987) Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet ii, 1057-1058
38. Kubes, P., Suzuki, M. and Granger, D. N. (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion, Proc. Natl. Acad. Sci. U.S.A. 88, 4651-4655
39. Fukumoto, Y., Urabe, Y., Kubo, T. et al. (2000) Augmented vasodilator response to L-arginine after coronary angioplasty may attenuate restenosis. Heart Vessels 16, 171-174
40. Wang, X. L., Sim, A. S., Badenhop, R. F., McCredie, R. M. and Wilcken, D. E. (1996) A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat. Med. 2, 41-45
41. Ryan, T. J., Bauman, W. B., Kennedy, J. W. et al. (1993) Guidelines for percutaneous transluminal coronary angioplasty. A report of the American Heart Association/American College of Cardiology task force on assessment of diagnostic and therapeutic procedures (Committee on percutaneous transluminal coronary angioplasty). Circulation 88, 2987-3007
42. Thomas, A. E., Green, F. R., Kelleher, C. H. et al. (1991) Variation in the promoter region of the β fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb. Haemostasis 65, 487-490
43. PIA, Ko, Bak and Br (HPA-1, 2, 3, 5). Br. J. Haematol. 89, 169-176
44. Falk, G., Almquist, A., Nordenhem, S. H., Svensson, H. and Wiman, B. (1995) Allele specific PCR for detection of a sequence polymorphism in the promotor region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 9, 170-174
45. Zoller, B., Svensson, P. J., He, X. and Dahlback, B. (1994) Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J. Clin. Invest. 94, 2521-2524
46. Gallagher, G., Eskdale, J., Oh, H. H., Richards, S. D., Campbell, D. A. and Field, M. (1997) Polymorphisms in the TNF gene cluster and MHC serotypes in the West of Scotland. Immunogenetics 45, 188-194
47. Deng, G. Y., Maclaren, N. K., Huang, H. S., Zhang, L. P. and She, J. X. (1996) No primary association between the 308 polymorphism in the tumor necrosis factor α promoter region and insulin-dependent diabetes mellitus. Hum. Immunol. 45, 137-142
48. Kornman, K. S., Crane, A., Wang, H. Y. et al. (1997) The interleukin-1 genotype as a severity factor in aduli periodontal disease. J. Clin. Periodontol. 24, 72-77
49. Frosst, P., Blom, H. J., Milos, R. et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Gen. 10, 111-113
50. Ichihara, S., Yamada, Y., Fujimura, T., Nakashima, N. and Yokota, M. (1998) Association of a polymorphism of the endothelial constitutive nitric oxide synthase gene with myocardial infarction in the Japanese population. Am. J. Cardiol. 81, 83-86
51. Di Castelnuovo, A., de Gaetano, G., Donati, M. B. and Iacoviello, L. (2001) Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb. Haemostasis 85, 626-633
52. Ortlepp, J. R., Hoffmann, R., Killian, A., Lauscher, J., Merkelbach-Bruse, S. and Hanrath, P. (2001) The 4G/5G promotor polymorphism of the plasminogen activator inhibitor-1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients. Clin. Cardiol. 24, 585-591
53. Bonnici, F., Keavney, B., Collins, R. and Danesh, J. (2002) Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies. Br. Med. J. 325, 517-520
54. Francis, S. E., Camp, N. J., Burton, A. J. et al. (2001) Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty. Heart 86, 336-340
55. Kastrati, A., Koch, W., Berger, P. B. et al. (2000) Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J. Am. Coll. Cardiol. 36, 2168-2173
56. Van Bockxmeer, F. M., Mamotte, C. D., Vasikaran, S. D. and Taylor, R. R. (1997) Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 95, 21-23
57. Abbate, R., Sardi, I., Pepe, G. et al. (1998) The high prevalence of thermolabile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb. Haemostasis 79, 727-730
58. Abbate, R., Marcucci, R., Camacho-Vanegas, O. et al. (1998) Role of platelet glycoprotein PL(A1/A2) polymorphism in restenosis after percutaneous transluminal coronary angioplasty. Am. J. Cardiol. 82, 524-525
59. Kosokabe, T., Okumura, K., Sone, T. et al. (2001) Relation of a common methylenetetrahydrofolate reductase mutation and plasma liomocysteine with intimal hyperplasia after coronary stenting. Circulation 103, 2048-2054
60. Hermans, W. R. M., Foley, D. P., Rensing, B. J. and Serruys, P. W. (1994) Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions: further evidence for the restenosis paradox. Am. Heart J. 127, 483-494
61. Hirshfeld, J. W., Schwartz, S., Jugo, R. et al. (1991) Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. J. Am. Coll. Cardiol. 18, 647-656
62. Faxon, D. P. (1995) Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J. Am. Coll. Cardiol. 25, 362-369